[{"arm_notes": "", "treatment_id": null, "treatment_name": "Treatment: Other- Mesenchymoangioblast-derived mesenchymal stem cells (CYP-001)Intervention group: Mesenchymoangioblast-derived mesenchymal stem cells (CYP-001) at a dose of 2 million cells/kg (up to a maximum of 200 million cells) by IV infusion on two occasions (Day 1 and Day 3) PLUS standard of care in ICUControl group: standard of care in ICUThe active agent in CYP-001 is allogeneic mesenchymoangioblast-derived mesenchymal stem cells (MCA-derived MSCs); which are produced using the proprietary Cymerus\u2122 platform technology. Cymerus\u2122 refers to the process of generating cell-based products from intermediate cells; MCAs; which in turn are derived from induced pluripotent stem cells or iPSCs. The iPSCs used in the Cymerus\u2122 process were derived from blood donated by a fully-consented healthy adult donor; and were reprogrammed using a transgene-free; viral-free and feeder-free technique.The PI or authorised designee will ensure that the study treatment at site is safely handled and administered in compliance with requirements. The infusion of the treatment itself will last no longer than 40 minutes; at a rate of 1mL/min; administered via ICU staff.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 367, "treatment_name": "Cyp-001", "treatment_type": "Advanced therapy medicinal products (atmp)", "pharmacological_treatment": "Biological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]